Effects of cold ischemia and inflammatory tumor microenvironment on detection of PI3K/AKT and MAPK pathway activation patterns in clinical cancer samples

International Journal of Cancer

Volumn 131, Issue 7, 2012, Pages 1621-1632

  Bonnas, Christel ^a,e   Specht, Katja ^b   Spleiss, Olivia ^a,e   Froehner, Stefanie ^c   Dietmann, Gabriele ^a,e   Krüger, Juliane M ^a,e   Arbogast, Susanne ^a,e   Feuerhake, Friedrich ^a,d,e  

^a ROCHE INNOVATION CENTER MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e NONE

Author keywords

biopsy; cancer; duplex immunohistochemistry; image analysis; mutation; pAKT; pERK

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TUMOR MARKER;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CELL CULTURE; COLD ISCHEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MASTECTOMY; MOUSE; NEEDLE BIOPSY; NONHUMAN; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

ANIMALS; BIOPSY; BREAST NEOPLASMS; CELL LINE, TUMOR; COLD ISCHEMIA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASES; MUTATION; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; TUMOR MICROENVIRONMENT;

EID: 84864425703     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27422     Document Type: Article

References (34)

1. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010; 467: 596-9.
2. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB,. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-19.
3. Cully M, You H, Levine AJ, Mak TW,. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 2006; 6: 184-92.
4. Wagner EF, Nebreda AR,. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009; 9: 537-49.
5. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773: 1263-84.
6. Bos JL,. ras oncogenes in human cancer: a review. Cancer Res 1989; 49: 4682-9.
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
8. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009; 16: 21-32.
9. Yuan TL, Cantley LC,. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-510.
10. Fresno Vara JA, Casado E, de CJ, Cejas P, Belda-Iniesta C, Gonzalez-Baron M,. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30: 193-204.
11. Dhillon AS, Hagan S, Rath O, Kolch W,. MAP kinase signalling pathways in cancer. Oncogene 2007; 26: 3279-90.
12. Hanahan D, Weinberg RA,. The hallmarks of cancer. Cell 2000; 100: 57-70.
13. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, Heynck S, Stuckrath I, Weiss J, Fischer F, Michel K, Goel A, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci USA 2009; 106: 18351-6.
14. Navin N, Krasnitz A, Rodgers L, Cook K, Meth J, Kendall J, Riggs M, Eberling Y, Troge J, Grubor V, Levy D, Lundin P, et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010; 20: 68-80.
15. Cicenas J, Urban P, Vuaroqueaux V, Labuhn M, Kung W, Wight E, Mayhew M, Eppenberger U, Eppenberger-Castori S,. Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2. Breast Cancer Res 2005; 7: R394-401.
16. Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, Esserman LJ, Belluco C, et al. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res 2008; 7: 1508-17.
17. Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A'hern R, Nerurkar A, Osin P, Smith IE, Dowsett M,. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 2010; 12: R76.
18. Mandell JW,. Immunohistochemical assessment of protein phosphorylation state: the dream and the reality. Histochem Cell Biol 2008; 130: 465-71.
19. Mandell JW,. Phosphorylation state-specific antibodies: applications in investigative and diagnostic pathology. Am J Pathol 2003; 163: 1687-98.
20. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, Lyon A, Bartlett JM,. AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 2005; 207: 139-46.
21. Gee JM, Robertson JF, Ellis IO, Nicholson RI,. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001; 95: 247-54.
22. Yonemori K, Tsuta K, Shimizu C, Hatanaka Y, Hashizume K, Ono M, Kouno T, Ando M, Tamura K, Katsumata N, Hasegawa T, Kinoshita T, et al. Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. Med Oncol 2009; 26: 344-9.
23. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43.
24. R Development Core Team. R: a language and environment for statistical computing. R-project org 2003. Available at:.
25. Juhl H,. Preanalytical aspects: a neglected issue. Scand J Clin Lab Invest Suppl 2010; 242: 63-5.
26. Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, Deng J, VanMeter AJ, Geho DH, Pastore L, Sennesh J, et al. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics 2008; 7: 1998-2018.
27. Baker AF, Dragovich T, Ihle NT, Williams R, Fenoglio-Preiser C, Powis G,. Stability of phosphoprotein as a biological marker of tumor signaling. Clin Cancer Res 2005; 11: 4338-40.
28. Dragu A, Schnurer S, Surmann-Schmitt C, Unglaub F, Kneser U, Horch RE,. Expression of HIF-1alpha in ischemia and reperfusion in human microsurgical free muscle tissue transfer. Plast Reconstr Surg 2011; 127: 2293-300.
29. Roberts JR, Rowe PA, Demaine AG,. Activation of NF-kappaB and MAP kinase cascades by hypothermic stress in endothelial cells. Cryobiology 2002; 44: 161-9.
30. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, Sasazuki T, Solit DB, Rosen N,. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 2010; 18: 39-51.
31. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439: 358-62.
32. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008; 68: 9375-83.
33. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C, Stegmeier F,. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009; 69: 4286-93.
34. Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N,. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci USA 2009; 106: 4519-24.